Navigation Links
Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV
Date:2/18/2011

patients in this trial will either receive peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon alfa-2b (PegIntron®) and ribavirin (Rebetol®) as part of their treatment. A third global, phase 3, double-blind randomized study, known as TMC435-C3007 or PROMISE (PROtease inhibitor TMC435 In PatientS who have previously rElapsed on IFN/RBV), will evaluate a single TMC435 once-daily oral tablet (150 mg) verses placebo in HCV patients who experienced viral relapse after previous interferon-based therapy. Both groups will receive peginterferon alfa-2a (Pegasys®) and ribavirin (Copegus®). The complete treatment duration for all three trials will be 24 or 48 weeks, depending on patient response.

The studies will be conducted at more than 160 sites in 24 countries, including the U.S. and countries throughout Europe, and together seek to enroll approximately 1,125 HCV genotype 1 infected patients who are treatment-naive or have experienced a relapse after previous interferon-based HCV therapy. To be eligible, patients must have chronic hepatitis C infection, and must have had a liver biopsy within three years of the screening visit. For those patients who have not had a liver biopsy in the three years prior to the study, one will be performed before the baseline visit. In addition, eligible patients need to have completed a recent ultrasound with no findings suspicious of hepatocellular carcinoma (HCC). Patients with signs of hepatic decompensation, liver disease of any non-HCV etiology, co-infection with hepatitis B or HIV-1 and 2 or a history of malignancy within 5 years of the screening vitis are ineligible for the study. Patients in QUEST-1 and QUEST-2 trials must not have received any prior treatment for hepatitis C, and patients in the PROMISE trial must have previously received at least 24 weeks of (peg)interferon-based therapy, along with documented negative HCV RNA at last o
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
5. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
6. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
7. Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS
8. Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers
9. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
10. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
11. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 ... has announced the addition of the  "Global ...  report to their offering.  ... Chinese Acne Medication Industry Report 2014 is ... current state of the global acne medication ...
(Date:10/22/2014)... CLARA, Calif. , Oct. 22, 2014  Cephasonics, ... announced the introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), ... white-label ultrasound systems designed and manufactured by Cephasonics for ... name and model number. Cephasonics will be showcasing the ... being held this week in Chongqing, China ...
(Date:10/22/2014)... -- Charlene Vernak, RPh, of Vernak Farms Pharmacy in ... the George Roentsch Scholarship by the Professional Compounding Centers ... Houston during PCCA,s International Seminar, held ... an independent pharmacist and PCCA member who embodies the ... a well-known pharmacist in the compounding community. ...
Breaking Medicine Technology:Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2
... NEW YORK, Nov. 7, 2011 Delcath Systems (NASDAQ: ... the fiscal 2011 third quarter ended September 30, 2011. ... Research & Development:  Accelerated development ... system, which has demonstrated significantly higher filtration efficiency of ...
... 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... ended September 30, 2011 and provided a business update. ... 2011 and 2010, as reported in accordance with accounting ... $13.4 million and $0.6 million, respectively.  The net losses ...
Cached Medicine Technology:Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 2Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 3Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 4Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 5Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 6Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 7Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments 8Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 2Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 3Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 4Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 5Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 6Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 7
(Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... -- Interrupting blood supply to an arm or a leg ... the surgery, according to a new study. "During ... the heart to be able to operate on it. After ... ability to produce energy because it doesn,t get oxygen. When ... such as an arm or a leg, the body prepares ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... 23, 2014 (HealthDay News) -- A large influx of ... is to avoid tens of thousands of deaths from ... researchers predict. Using a specially designed mathematical ... the outbreak in just one densely populated county of ... city of Monrovia. The researchers said that if ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... Despite initiatives, level of diversity among faculty, practitioners still ... say , ANN ARBOR, Mich. , Jan. ... medical school faculty remains low, even as the U.S. population ... currently being trained in medicine is unlikely to reverse those ...
... , Jan. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... in 2010. Each of the dividends will be $0.50 per share. ... to all stockholders who own shares of PDL on March 15, 2010 ... October 1, 2010 to all stockholders who own shares of PDL on ...
... , ... of Hematology (ASH) now offers physicians who diagnose and treat ... (CME) credits while staying abreast of the latest clinical strategies ... with Medscape, an online network of medical content for physicians ...
... , BRIGHTON, Mich. , ... alcohol and drug treatment provider in North America, has signed a ... a Saudi Arabian company to build a 291,000 square-foot, 250 ... the entire Islamic Mideast. , Brighton Hospital, the Addiction Treatment ...
... for ovarian cancer does not appear to detect early-stage ovarian ... 1 out of 100 women in the general population with ... in the Journal of the National Cancer Institute . ... in Seattle assessed the predictive value of certain symptoms, including ...
... vaccine developed using non-infectious virus-like particles (VLP) has ... mosquito-borne pathogen that has infected millions of people ... researchers at the National Institutes of Health have ... Allergy and Infectious Diseases (NIAID) developed the vaccine ...
Cached Medicine News:Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 2Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 3Health News:PDL BioPharma Announces Two $0.50 Dividends in 2010 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 2Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 4Health News:Symptoms have little value for early detection of ovarian cancer 2Health News:Virus-like particle vaccine protects monkeys from chikungunya virus 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: